57.50
0.33 (0.58%)
| Previous Close | 57.17 |
| Open | 57.66 |
| Volume | 1,376,747 |
| Avg. Volume (3M) | 2,154,039 |
| Market Cap | 11,027,120,128 |
| Price / Earnings (TTM) | 21.30 |
| Price / Earnings (Forward) | 13.61 |
| Price / Sales | 3.82 |
| Price / Book | 1.90 |
| 52 Weeks Range | |
| Earnings Date | 4 Aug 2025 - 8 Aug 2025 |
| Profit Margin | 17.76% |
| Operating Margin (TTM) | 30.05% |
| Diluted EPS (TTM) | 2.70 |
| Quarterly Revenue Growth (YOY) | 14.80% |
| Quarterly Earnings Growth (YOY) | 109.40% |
| Total Debt/Equity (MRQ) | 10.39% |
| Current Ratio (MRQ) | 5.52 |
| Operating Cash Flow (TTM) | 700.26 M |
| Levered Free Cash Flow (TTM) | 411.56 M |
| Return on Assets (TTM) | 6.38% |
| Return on Equity (TTM) | 9.64% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bearish | Bearish |
| Biotechnology (Global) | Bearish | Bearish | |
| Stock | BioMarin Pharmaceutical Inc. | Bearish | Bearish |
AIStockmoo Score
| Analyst Consensus | 3.0 |
| Insider Activity | NA |
| Price Volatility | 0.5 |
| Technical Moving Averages | 1.5 |
| Technical Oscillators | 2.0 |
| Average | 1.75 |
|
BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments aimed at addressing complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria (PKU), hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Mid Growth |
| % Held by Insiders | 0.77% |
| % Held by Institutions | 98.91% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 104.00 (Goldman Sachs, 80.87%) | Buy |
| Median | 91.00 (58.26%) | |
| Low | 78.00 (Citigroup, 35.65%) | Hold |
| Average | 91.00 (58.26%) | |
| Total | 1 Buy, 1 Hold | |
| Avg. Price @ Call | 62.05 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Goldman Sachs | 05 May 2025 | 104.00 (80.87%) | Buy | 62.06 |
| Citigroup | 02 May 2025 | 78.00 (35.65%) | Hold | 62.03 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 01 Jul 2025 | Announcement | BioMarin Announces Completion of Acquisition of Inozyme |
| 24 Jun 2025 | Announcement | BioMarin Presents Five-Year Phase 3 Results Reinforcing Long-Term Efficacy and Safety of ROCTAVIAN® (valoctocogene roxaparvovec-rvox) at International Society on Thrombosis and Haemostasis 2025 Congress |
| 16 May 2025 | Announcement | BioMarin Strengthens Enzyme Therapy Business with Acquisition of Inozyme Pharma |
| 12 May 2025 | Announcement | BioMarin Presents New Data for VOXZOGO® (vosoritide) in Children with Achondroplasia and Other Skeletal Conditions at Two International Endocrinology Meetings |
| 01 May 2025 | Announcement | BioMarin Reports First Quarter 2025 Results and Reaffirms Full-year Guidance |
| 17 Apr 2025 | Announcement | BioMarin to Host First Quarter 2025 Financial Results Conference Call and Webcast on Thursday, May 1, 2025, at 4:30pm ET |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |